Great Lakes Advisors’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,621
| Closed | -$258K | – | 797 |
|
|
2025
Q2 | $258K | Buy |
2,621
+311
| +13% | +$29.4K | ﹤0.01% | 728 |
|
|
2025
Q1 | $214K | Buy |
+2,310
| New | +$213K | ﹤0.01% | 758 |
|
|
2024
Q4 | – | Sell |
-52,129
| Closed | -$5.03M | – | 817 |
|
|
2024
Q3 | $5.03M | Sell |
52,129
-77,367
| -60% | -$7.55M | 0.04% | 325 |
|
|
2024
Q2 | $11.9M | Sell |
129,496
-7,863
| -6% | -$730K | 0.11% | 179 |
|
|
2024
Q1 | $12.7M | Buy |
137,359
+807
| +0.6% | +$75.6K | 0.11% | 179 |
|
|
2023
Q4 | $13M | Sell |
136,552
-2,476
| -2% | -$231K | 0.12% | 172 |
|
|
2023
Q3 | $13M | Sell |
139,028
-1,413
| -1% | -$131K | 0.12% | 165 |
|
|
2023
Q2 | $12.8M | Buy |
140,441
+3,087
| +2% | +$253K | 0.13% | 181 |
|
|
2023
Q1 | $10.1M | Buy |
+137,354
| New | +$11.9M | 0.09% | 217 |
|
|
2022
Q1 | – | Sell |
-1,726
| Closed | -$279K | – | 704 |
|
|
2021
Q4 | $279K | Sell |
1,726
-62,694
| -97% | -$10.1M | ﹤0.01% | 601 |
|
|
2021
Q3 | $9.61M | Sell |
64,420
-2,823
| -4% | -$587K | 0.15% | 191 |
|
|
2021
Q2 | $16.5M | Sell |
67,243
-2,397
| -3% | -$629K | 0.25% | 131 |
|
|
2021
Q1 | $18.4M | Sell |
69,640
-32,690
| -32% | -$9.22M | 0.3% | 106 |
|
|
2020
Q4 | $30M | Sell |
102,330
-4,350
| -4% | -$1.12M | 0.54% | 46 |
|
|
2020
Q3 | $25.2M | Buy |
106,680
+16,037
| +18% | +$3.65M | 0.53% | 50 |
|
|
2020
Q2 | $18M | Sell |
90,643
-15,477
| -15% | -$2.89M | 0.44% | 68 |
|
|
2020
Q1 | $19.5M | Buy |
106,120
+3,234
| +3% | +$575K | 0.57% | 46 |
|
|
2019
Q4 | $17.2M | Buy |
102,886
+32,775
| +47% | +$4.87M | 0.37% | 64 |
|
|
2019
Q3 | $9.19M | Buy |
70,111
+2,901
| +4% | +$378K | 0.2% | 127 |
|
|
2019
Q2 | $8.16M | Sell |
67,210
-54,933
| -45% | -$6.52M | 0.18% | 137 |
|
|
2019
Q1 | $15.1M | Sell |
122,143
-17,822
| -13% | -$2.24M | 0.34% | 64 |
|
|
2018
Q4 | $16.4M | Buy |
139,965
+23,680
| +20% | +$2.79M | 0.39% | 59 |
|
|
2018
Q3 | $14.5M | Sell |
116,285
-10,611
| -8% | -$1.17M | 0.32% | 63 |
|
|
2018
Q2 | $10.8M | Sell |
126,896
-1,233
| -1% | -$90.5K | 0.25% | 90 |
|
|
2018
Q1 | $7.73M | Buy |
128,129
+35,611
| +38% | +$2.03M | 0.18% | 123 |
|
|
2017
Q4 | $4.88M | Buy |
92,518
+13,534
| +17% | +$713K | 0.11% | 168 |
|
|
2017
Q3 | $4.42M | Buy |
78,984
+4,190
| +6% | +$222K | 0.1% | 171 |
|
|
2017
Q2 | $4.7M | Buy |
74,794
+12,453
| +20% | +$725K | 0.12% | 161 |
|
|
2017
Q1 | $3.19M | Buy |
+62,341
| New | +$2.97M | 0.08% | 206 |
|
Other funds holding AMED
IA
MCI
HNB
Great Lakes Advisors's AMED Position: Q3 2025 in Review
Great Lakes Advisors sold out of Amedisys (AMED) in Q3 2025, closing a stake of 2,621 shares — an estimated $258K sold.
Great Lakes Advisors first reported a position in AMED in Q1 2017 and held it in 29 quarters. The position peaked at $30M in Q4 2020. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.
- Great Lakes Advisors reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
- Great Lakes Advisors sold 2,621 Amedisys shares in Q3 2025, an estimated $258K.
- Great Lakes Advisors first reported a position in Amedisys in Q1 2017 and held it in 29 quarters.
- Great Lakes Advisors's Amedisys position peaked at $30M in Q4 2020.
- 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.
Based on Great Lakes Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.